The DOI matches its Crossref record; 37 of the 43 references it cites were found in a registry or an index.
Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
Open accessPublished version of a preprint
Abstract
Purpose: Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer. We determined the extent to which these 4 alterations are coexistent in the same carcinoma, and their impact on patient outcome. Experimental Design: Pancreatic cancer patients who underwent an autopsy were studied (n = 79). Matched primary and metastasis tissues were evaluated for intragenic mutations in KRAS, CDKN2A, and TP53 and immunolabeled for CDKN2A, TP53, and SMAD4 protein products. The number of altered driver genes in each carcinoma was correlated to clinicopathologic features. Kaplan–Meier estimates were used to determine median disease free and overall survival, and a Cox proportional hazards model used to compare risk factors. Results: The number of genetically altered driver genes in a carcinoma was variable, with only 29 patients (37%) having an alteration in all 4 genes analyzed. The number of altered driver genes was significantly correlated with disease free survival (P = 0.008), overall survival (P = 0.041), and metastatic burden at autopsy (P = 0.002). On multivariate analysis, the number of driver gene alterations in a pancreatic carcinoma remained independently associated with overall survival (P = 0.046). Carcinomas with only 1 to 2 driver alterations were enriched for those patients with the longest survival (median 23 months, range 1 to 53). Conclusions: Determinations of the status of the 4 major driver genes in pancreatic cancer, and specifically the extent to which they are coexistent in an individual patients cancer, provides distinct information regarding disease progression and survival that is independent of clinical stage and treatment status. Clin Cancer Res; 18(22); 6339–47. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Coexistent alterations in CDKN2A, KRAS, TP53 and SMAD4 were observed in pancreatic cancer, with frequent loss of tumor suppressors like CDKN2A, ARID1A, APC and ID3 [26,44].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Self-citationCaldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Self-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Self-citationAguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 4×
“Furthermore, although genetically engineeredmousemodels indicate that the concomitant expression of thesemutated genes is crucial to progress to invasion and metastasis in PDACs (15–19), the extent to which the coexistence of 3 or more of these altered genes in the same PDAC influence thebiologic behavior and survival…”
BackgroundInfluential
Cited by
Sorted by citations
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Self-citationLaklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G., Barrett, A., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 614
Self-citationPancreatic cancer biology and genetics from an evolutionary perspective
Makohon-Moore, A. P., & Iacobuzio–Donahue, C. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.66 · Cited by 436
Self-citationMakohon-Moore, A. P., Zhang, M., Reiter, J. G., Bozic, I., Allen, B., Kundu, D., Chatterjee, K., Wong, F., Jiao, Y., Kohutek, Z. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3764 · Cited by 403
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 334
Karamitopoulou, E. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0479-5 · Cited by 305
Qian, Z. R., Rubinson, D. A., Nowak, J. A., Morales-Oyarvide, V., Dunne, R. F., Kozak, M. M., Welch, M. W., Brais, L. K., Da Silva, A., Li, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3420 · Cited by 260
Kim-Fuchs, C., Le, C. P., Pimentel, M. A., Shackleford, D., Ferrari, D., Angst, E., Hollande, F., & Sloan, E. K. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.02.019 · Cited by 287
Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes
Maurer, C., Holmstrom, S. R., He, J., Laise, P., Su, T., Ahmed, A., Hibshoosh, H., Chabot, J. A., Oberstein, P. E., Sepulveda, A. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317706 · Cited by 216
Advanced-stage pancreatic cancer: therapy options
Werner, J., Combs, S. E., Springfeld, C., Hartwig, W., Hackert, T., & Büchler, M. W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.66 · Cited by 220
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 218
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Self-citationHayashi, A., Fan, J., Chen, R., Ho, Y.-J., Makohon-Moore, A. P., Lecomte, N., Zhong, Y., Hong, J., Huang, J., Sakamoto, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0010-1 · Cited by 205
Self-citationRUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma
Whittle, M. C., Izeradjene, K., Rani, P. G., Feng, L., Carlson, M. A., DelGiorno, K. E., Wood, L. D., Goggins, M., Hruban, R. H., Chang, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.048 · Cited by 203
Self-citationNew therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Agostino, S. D. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 203
Organoid models of gastrointestinal cancers in basic and translational research
Lau, H. C.-H., Kranenburg, O., Xiao, H., & Yu, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0255-2 · Cited by 205
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Takai, E., Totoki, Y., Nakamura, H. K., Morizane, C., Nara, S., Hama, N., Suzuki, M., Furukawa, E., Kato, M., Hayashi, H., et al. (2015) · Scientific Reports · doi:10.1038/srep18425 · Cited by 196
Self-citationEvolution and dynamics of pancreatic cancer progression
Yachida, S., & Iacobuzio–Donahue, C. A. (2013) · Oncogene · doi:10.1038/onc.2013.29 · Cited by 185
Self-citationNew Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
Coriat, R., Walter, T., Terris, B., Couvelard, A., & Ruszniewski, P. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0476 · Cited by 151
Molecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 134
Therapeutic options for the management of pancreatic cancer
Rossi, M. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11142 · Cited by 130
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 128
The Evolutionary Origins of Recurrent Pancreatic Cancer
Sakamoto, H., Attiyeh, M. A., Gerold, J. M., Makohon-Moore, A. P., Hayashi, A., Hong, J., Kappagantula, R. L., Zhang, L., Melchor, J. P., Reiter, J. G., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1508 · Cited by 123
Self-citationEmerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 126
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 121
Luchini, C., Pea, A., Lionheart, G., Mafficini, A., Nottegar, A., Veronese, N., Chianchiano, P. E., Brosens, L. A. A., Noë, M., Offerhaus, G. J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4941 · Cited by 113
Schlitter, A. M., Segler, A., Steiger, K., Michalski, C. W., Jäger, C., Konukiewitz, B., Pfarr, N., Endris, V., Bettstetter, M., Kong, B., et al. (2017) · Scientific Reports · doi:10.1038/srep41064 · Cited by 122
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma
Wang, W.-Q., Liu, L., Xu, H.-X., Wu, C.-T., Xiang, J.-F., Xu, J., Liu, C., Long, J., Ni, Q.-X., & Yu, X. (2016) · British journal of surgery · doi:10.1002/bjs.10187 · Cited by 114
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
Giovannetti, E., van der Borden, C. L., Frampton, A. E., Ali, A., Firuzi, O., & Peters, G. J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.006 · Cited by 114
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 113
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
Houg, D. S., & Bijlsma, M. F. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0842-9 · Cited by 114
Dal Molin, M., Zhang, M., de Wilde, R. F., Ottenhof, N. A., Rezaee, N., Wolfgang, C. L., Blackford, A., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2600 · Cited by 101
Self-citationWatanabe, F., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Takayama, Y., Ishikawa, H., Kakizawa, N., Saito, M., Futsuhara, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227366 · Cited by 100
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
Rovithi, M. N., Avan, A., Funel, N., León, L. G., Gómez‐Mellado, V. E., Wurdinger, T. D., Griffioen, A. W., Verheul, H. M. W., & Giovannetti, E. (2017) · Scientific Reports · doi:10.1038/srep44686 · Cited by 93
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98
Ideno, N., Yamaguchi, H., Ghosh, B., Gupta, S., Okumura, T., Steffen, D. J., Fisher, C. G., Wood, L. D., Singhi, A. D., Nakamura, M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.006 · Cited by 80
Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
Large, T. Y. S. L., Bijlsma, M. F., Geert Kazemier, M., van Laarhoven, H. W. M., Giovannetti, E., & Jiménez, C. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.008 · Cited by 93
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 92
Elhanafi, S. E., Mahmud, N., Vergara, N., Kochman, M. L., Das, K. K., Ginsberg, G. G., Rajala, M. W., & Chandrasekhara, V. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14540 · Cited by 87
Pathology of pancreatic ductal adenocarcinoma: Facts, challenges and future developments
Esposito, I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.13833 · Cited by 95
Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus
Yuan, C., Rubinson, D. A., Qian, Z. R., Wu, C. H., Kraft, P. L., Bao, Y., Ogino, S., Ng, K., Clancy, T. E., Swanson, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5688 · Cited by 87
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Neeße, A., Gress, T. M., Tuveson, D. A., Michl, P., & Krug, S. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38111 · Cited by 87
Bijlsma, M. F., & van Laarhoven, H. W. M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9541-1 · Cited by 84
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Flynt, E., Bisht, K. K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020) · Cells · doi:10.3390/cells9020287 · Cited by 79
Baek, B., & Lee, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-76025-1 · Cited by 79
HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties
Abel, E. V., Goto, M., Magnuson, B., Abraham, S. T., Ramanathan, N., Hotaling, E., Alaniz, A. A., Kumar‐Sinha, C., Dziubinski, M. L., Urs, S., et al. (2018) · eLife · doi:10.7554/elife.33947 · Cited by 73
Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis
Frankowski, K. J., Wang, C., Patnaik, S., Schoenen, F. J., Southall, N. T., Li, D., Teper, Y., Sun, W., Kandela, I. K., Hu, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8307 · Cited by 73
Zhang, W., Xing, J., Liu, T., Zhang, J., Dai, Z., Zhang, H., Wang, D., & Tang, D. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00806-y · Cited by 71
Huang, X., Zhou, S., Liu, Y., Tóth, J., & András, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978865 · Cited by 68
Oshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102871 · Cited by 64
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Crane, C. H., Li, D., Evans, D. B., Maitra, A., & Tsai, S. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094 · Cited by 64
Ischenko, I., Petrenko, O., & Hayman, M. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319911111 · Cited by 62
Lee, J., Snyder, E. R., Liu, Y., Gu, X., Wang, J., Flowers, B. M., Kim, Y. J., Park, S., Szot, G. L., Hruban, R. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14686 · Cited by 64
Self-citationLiquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 62
Ideno, N., Ohtsuka, T., Matsunaga, T., Kimura, H., Watanabe, Y., Tamura, K., Aso, T., Aishima, S., Miyasaka, Y., Ohuchida, K., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000258 · Cited by 60
Duconseil, P., Gilabert, M., Gayet, O., Loncle, C., Moutardier, V., Turrini, O., Calvo, E. L., Ewald, J., Giovannini, M. F., Gasmi, M., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.11.029 · Cited by 56
Valero, V., Saunders, T., He, J. P., Weiss, M. J., Cameron, J. L., Dholakia, A. S., Wild, A. T., Shin, E. J., Khashab, M. A., Lennon, A. M., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001156 · Cited by 55
Self-citationPre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
Markov, S. D., Perales-Patón, J., Bockorny, B., Dopazo, A., Muñoz, M., Baños, N., Bonilla, V., Menéndez, C., Durán, Y., Huang, L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1166 · Cited by 50
Zhong, Y., Macgregor‐Das, A. M., Saunders, T., Whittle, M. C., Makohon-Moore, A. P., Kohutek, Z. A., Poling, J., Herbst, B. T., Javier, B. M., Cope, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1615 · Cited by 46
Self-citationKameta, E., Sugimori, K., Kaneko, T., Ishii, T., Miwa, H., Sato, T. A., Ishii, Y., Sue, S., Sasaki, T., Yamashita, Y., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5168 · Cited by 47
Large, T. Y. S. L., Bijlsma, M. F., Hassouni, B. E., Mantini, G., Lagerweij, T., Henneman, A. A., Funel, N., Kok, B., Pham, T. V., Haas, R. D. G.-D., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01892-z · Cited by 44
Farran, B., & Nagaraju, G. P. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.07.001 · Cited by 45
Zhong, Y., Naito, Y., Cope, L., Naranjo‐Suarez, S., Saunders, T., Hong, S., Goggins, M., Herman, J. M., Wolfgang, C. L., & Iacobuzio–Donahue, C. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2823 · Cited by 44
Self-citationA MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Ischenko, I., Petrenko, O., & Hayman, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4538 · Cited by 42
Koujima, T., Tazawa, H., Ieda, T., Araki, H., Fushimi, T., Shoji, R., Kuroda, S., Kikuchi, S., Yoshida, R., Umeda, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.016 · Cited by 48
Bouchart, C., Navez, J., Closset, J., Hendlisz, A., Gestel, D. V., Moretti, L., & Laethem, J. V. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936093 · Cited by 43
Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Franck, C., Müller, C., Rosania, R., Croner, R. S., Pech, M., & Venerito, M. (2020) · Cancers · doi:10.3390/cancers12071955 · Cited by 41
The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer
Fujii, A., Masuda, T., Iwata, M., Tobo, T., Wakiyama, H., Koike, K., Kosai, K., Nakano, T., Kuramitsu, S., Kitagawa, A., et al. (2021) · Cancer Science · doi:10.1111/cas.14858 · Cited by 41
Autophagy, p53, and Pancreatic Cancer
Iacobuzio–Donahue, C. A., & Herman, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1400189 · Cited by 41
Self-citationAllaway, R. J., Fischer, D. A., Abreu, F. B. D., Gardner, T. B., Gordon, S. R., Barth, R. J., Colacchio, T. A., Wood, M. D., Kacsoh, B. Z., Bouley, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7718 · Cited by 41
Lin, T., Ren, Q., Zuo, W., Jia, R., Xie, L., Lin, R., Zhao, H., Chen, J., Yan, L., Wang, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1160-9 · Cited by 40
Perkhofer, L., Walter, K., Costa, I. G., Carrasco, M. C. R., Eiseler, T., Hafner, S., Genze, F., Zenke, M., Bergmann, W., Illing, A., et al. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.08.007 · Cited by 39
Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future
Barhli, A., Cros, J. F., Bartholin, L., & Neuzillet, C. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.009 · Cited by 40
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 41
Evolving pancreatic cancer treatment: From diagnosis to healthcare management
Milella, M., Bassi, C., Boggi, U., Brunetti, O., Cavaliere, A., Crippa, S., Vita, F. D., Falconi, M., Frassineti, G. L., Giommoni, E., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103571 · Cited by 37
Tanaka, T., Masuda, A., Inoue, J., Hamada, T., Ikegawa, T., Toyama, H., Sofue, K., Shiomi, H., Sakai, A., Kobayashi, T., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-022-01939-8 · Cited by 36
Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Luckett, T., Abudula, M., Ireland, L., Glenn, M. A., Bellomo, G., Stafferton, R., Halloran, C. M., Ghaneh, P., Jones, R. P., Schmid, M. C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1542 · Cited by 37
Murphy, S. J., Hart, S. N., Halling, G. C., Johnson, S. H., Smadbeck, J. B., Drucker, T., Lima, J. F., Rohakhtar, F. R., Harris, F. R., Kosari, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2198 · Cited by 37
Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression
Zabransky, D. J., Chhabra, Y., Fane, M. E., Kartalia, E., Leatherman, J. M., Hüser, L., Zimmerman, J. W., Delitto, D., Han, S., Armstrong, T. D., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0086 · Cited by 38
Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases
Bechard, M. E., Word, A. E., Tran, A. V., Liu, X., Locasale, J. W., & McDonald, O. G. (2018) · Oncogene · doi:10.1038/s41388-018-0346-5 · Cited by 35
Ischyropoulou, M., Sabljo, K., Schneider, L., Niemeyer, C. M., Napp, J., Feldmann, C., & Alves, F. (2023) · Advanced Materials · doi:10.1002/adma.202305151 · Cited by 35
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Early diagnosis of pancreatic cancer: Current trends and concerns
Hanada, K., Amano, H., & Abe, T. (2017) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12004 · Cited by 33
Nagai, K., Mizukami, Y., Omori, Y., Kin, T., Yane, K., Takahashi, K., Ono, Y., Sugitani, A., Karasaki, H., Shinohara, T., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0405-7 · Cited by 33
Xiang, J.-F., Wang, W.-Q., Liu, L., Xu, H., Wu, C., Yang, J., Qi, Z.-H., Wang, Y.-Q., Xu, J., Liu, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19222 · Cited by 31
RetractedKlassifikation und malignes Potenzial der zystischen Pankreastumoren
Esposito, I., Schlitter, A. M., Sipos, B., & Klöppel, G. (2014) · Der Pathologe · doi:10.1007/s00292-014-1971-6 · Cited by 29
Paiella, S., Malleo, G., Cataldo, I., Gasparini, C., Pastena, M. D., Marchi, G. D., Marchegiani, G., Rusev, B. C., Scarpa, A., Girelli, R., et al. (2017) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-017-1627-0 · Cited by 29
Hsieh, Y., Liu, T., Chou, C.-J., Chen, H., Lee, K., & Yang, P. (2019) · Genes · doi:10.3390/genes10100766 · Cited by 29
Shimada, Y., Kohno, T., Ueno, H., Ino, Y., Hayashi, H., Nakaoku, T., Sakamoto, Y., Kondo, S., Morizane, C., Shimada, K., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0194 · Cited by 28
Lu, S., Ahmed, T., Du, P., & Wang, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061201 · Cited by 27
Wang, H., Wang, X., Xu, L., Lin, Y., Zhang, J., & Cao, H. (2020) · Aging · doi:10.18632/aging.103958 · Cited by 26
Matsumura, K., Hayashi, H., Uemura, N., Ogata, Y., Liu, Z., Sato, H., Shiraishi, Y., Kuroki, H., Kitamura, F., Kaida, T., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101533 · Cited by 26
The ‘SPARC’ of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review)
ROSSI, M. K., Gnanamony, M., & Gondi, C. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3417 · Cited by 25
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib
Mao, L., Mou, Y., Hou, S., Cao, D., & Li, A. (2018) · Medicine · doi:10.1097/md.0000000000013113 · Cited by 25
Metadata
- Authors
- Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., Hruban, R. H., Klein, A. P., Jones, S., Velculescu, V., Wolfgang, C. L., & Iacobuzio-Donahue, C. A.
- Affiliations
- Kurume University (JP)
- Authors' Affiliations: Departments of 1Pathology, 2Oncology, 3Surgery, and 4Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, 5The Lugwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Medical Institutions, Baltimore, Maryland; 6National Cancer Center Research Institute, Tokyo; and 7Kurume University School of Medicine, Kurume, Fukuoka, Japan
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-11-14
- Volume
- 18
- Issue
- 22
- Pages
- 6339-6347
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3500447
- OpenAlex
- W2155563954
- Cited by
- 280
- References
- 43
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 17 · 2023: 22 · 2022: 27 · 2021: 33 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 23 · 2016: 15 · 2015: 22 · 2014: 15 · 2013: 12
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- Japan Society for the Promotion of Science (23390326, 24659612)
- National Cancer Institute (CA-101955, P20CA101955, R01CA140599, P50CA101955, R01-CA121113, CA-121113, CA140599, P50CA062924, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, driver gene alterations, KRAS, CDKN2A, TP53, SMAD4, long-term survival, disease-free survival, metastatic burden, prognostic factors, autopsy tissue
- MeSH terms
- Aged, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Proto-Oncogene Proteins, Risk Factors, Proportional Hazards Models, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Survivors, Disease-Free Survival, ras Proteins, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Burden, Smad4 Protein, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
